Search the Newsreel

BioNexus Gene Lab Corp (BGLC) director granted 16,129-share fully vested stock award

BioNexus Gene Lab Corp (BGLC) director Low Jook Yuen received a fully vested stock award of 16,129 shares of common stock on August 13, 2026, for services rendered. This equity compensation, granted under the company's 2025 Equity Incentive Plan, had no cash consideration and …

Nasdaq Firm Makes Historic Shift to Ethereum-Based Treasury

BioNexus Gene Lab Corp., a Nasdaq-listed biotech firm, has become the first to adopt an Ethereum-focused treasury strategy, following Ethereum's inclusion in the U.S. "Crypto Strategic Reserve." The company released a whitepaper detailing Ethereum's advantages as a financial infrastructure asset, citing its liquidity, utility, …

BioNexus Gene Lab Corp (BGLC) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for BioNexus Gene Lab Corp (BGLC), detailing estimated future EPS and revenue growth. It includes current stock information, such as the market capitalization and recent price movements, along with a list of peer companies for comparison. The content …

BioNexus Gene Lab files initial beneficial ownership statement for Fidelion Diagnostics Pte. Ltd

BioNexus Gene Lab has filed an initial beneficial ownership statement (Form 3) indicating that Fidelion Diagnostics Pte. Ltd. beneficially owns 392,329 common shares, classifying it as a greater-than-5% holder. This filing, signed by Ling Xiao, notes the ownership as of November 28, 2025, with …

Fidelion Diagnostics reports 392,329 BioNexus Gene Lab Corp (NASDAQ: BGLC) shares

Fidelion Diagnostics PTE. LTD. has reported direct ownership of 392,329 shares of BioNexus Gene Lab Corp (NASDAQ: BGLC) common stock, identifying itself as a greater than 5% holder. This Form 3 filing is an initial statement of holdings and does not indicate any recent …

BioNexus Gene Lab Corp (BGLC) Stock News Today

BioNexus Gene Lab names CFO Chong Set Fui in initial beneficial ownership filing

BioNexus Gene Lab has filed an initial Form 3 for its CFO, Chong Set Fui, dated June 17, 2025. This news brief was generated by Public Technologies using AI and is for informational purposes only, not financial advice. The original content was published via …

BioNexus Gene Lab (BGLC) CEO files Form 3 showing 0.0000 shares

BioNexus Gene Lab Corp (BGLC) CEO and director Tan Lee Su-Leng filed a Form 3, an initial statement of beneficial ownership of securities, reporting 0.0000 shares held directly. This filing, dated August 15, 2023, indicates no buy or sell transactions. The report clarifies that …

BioNexus Gene Lab Corp (BGLC) director reports holding 0 common shares

BioNexus Gene Lab Corp (BGLC) director Bin Abdul Hamid Muhammad Azrul filed a Form 3, an Initial Statement of Beneficial Ownership, reporting direct ownership of 0 shares of common stock as of December 11, 2023. The filing indicates no purchase, sale, or derivative transactions, …

BioNexus Gene Lab Corp (BGLC) Financial Health: Profitability & Balance Sheet Analysis

BioNexus Gene Lab Corp (BGLC) has a current financial score of 6.04, ranking 292 out of 384 in the Biotechnology & Medical Research industry, indicating a robust financial status despite low operating efficiency. The company's latest quarterly revenue significantly decreased year-over-year by 98.93% to …

BioNexus Gene Lab Corp (BGLC) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for BioNexus Gene Lab Corp (BGLC), assigning it a score of 2.70 out of 384 companies in the Biotechnology & Medical Research industry. Key metrics include a beta value of 2.20, indicating higher volatility compared to the S&P …

BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit

BioNexus Gene Lab Corp. announced progress in commercializing its VitaGuard™ molecular residual disease (MRD) platform in Southeast Asia after a working visit to Tongshu Gene's facilities in China. The visit involved technical planning and meetings with Chinese hospitals where VitaGuard is already in commercial …

BioNexus Says VitaGuard Blood Tests Could Cost Under $300

BioNexus (BGLC) is progressing with the commercialization of its VitaGuard™ molecular residual disease (MRD) liquid-biopsy platform in Southeast Asia, targeting an initial rollout in select medical hubs in 2026. The company anticipates the cost per VitaGuard test to be under US$300, aiming to make …

BioNexus Gene Lab Corp Revenue Breakdown – NASDAQ:BGLC

BioNexus Gene Lab Corp (NASDAQ: BGLC) revenue breakdown highlights Malaysia as the primary contributor, generating $5.83 million last year, down from $7.46 million the previous year. This information is derived from their financial statements, focusing on top segments and regional performance.

BioNexus Gene Lab Corp (BGLC) Cash Flow

This article provides a detailed cash flow statement for BioNexus Gene Lab Corp (BGLC), including quarterly and annual data for operating, investing, and financing activities. It also defines key cash flow terms and offers insights into BGLC's financial health, such as an operating cash …

BioNexus Gene Lab Corp (BGLC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of BioNexus Gene Lab Corp (BGLC), including major individual and corporate holders, their proportionate ownership, and recent activity. It also provides institutional shareholding data over several quarters, showing changes in the number of institutions and shares held. Key …

BioNexus Gene Lab Corp (BGLC) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of BioNexus Gene Lab Corp (BGLC), noting its current valuation score of 8.43, which ranks it 138 out of 386 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -1.02, while also stating …

BGLC|BioNexus Gene Lab Corp|Price:1.510|Chg%:-0.050

BioNexus Gene Lab Corp (BGLC) is a biotechnology company specializing in precision diagnostics and chemical solutions. While the stock has seen significant declines over various periods, its fundamentals are deemed healthy with significant growth potential, and it is considered fairly valued within the Biotechnology …

BioNexus Gene Lab Corp (BGLC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of BioNexus Gene Lab Corp (BGLC), evaluating its price momentum, support and resistance levels, and various technical indicators and moving averages. As of July 24, 2026, BGLC has a price momentum score of 4.76, trading between resistance at …